Related by context. All words. (Click for frequent words.) 69 Phase III Pivotal 67 Combination REOLYSIN R 67 Phase Ib IIa 67 Refractory Angina 66 CALERIE 65 LUMINATE 65 ENDEAVOR IV 65 CHARM Added 65 CALGB 65 Phase III HEAT 65 Phase #b/#a clinical 65 Surgical Mesh 65 Anticancer Drug 65 Phase III Psoriasis 65 Pivotal Phase III 64 Multicenter Randomized 64 Phase Ib II 64 Advanced Heart Failure 64 REALITY Trial 64 Pivotal Trial 64 CLARITY TIMI 64 BioNumerik 64 Initiates Phase 2b 64 Pivotal Clinical Trial 64 Phase IIb III 64 CHAMPION PCI 64 Phase IIIb clinical 64 CONQUER OB 64 multicenter randomized clinical 63 Acute Decompensated Heart Failure 63 Phase III AFFIRM 63 Eculizumab 63 Phase III Clinical Trial 63 Phase Ib clinical 63 Initiates Phase II 63 EchoCRT 63 Aflibercept 63 Prostate AdenoCarcinoma Treatment 63 Clinical Trial Data 63 Initiates Enrollment 63 Phase III Trial 63 Phase 2b kidney transplant 63 Phase III multicenter 63 Oral Fingolimod 63 atypical Hemolytic Uremic Syndrome 63 ENDEAVOR III 63 randomized controlled Phase 63 Phase 2b Clinical Trial 63 Prospective Randomized 63 phase IIa clinical 63 National Emphysema Treatment 63 Multicenter Phase 63 multicenter randomized controlled 63 Phase III Clinical Trials 63 AFRS TM 63 Current Controlled Trials 63 HORIZONS AMI 63 Medtronic CoreValve ® 63 Initiate Phase II 63 Phase III psoriasis 63 Aryplase 62 multicenter clinical 62 Dr. Kandzari 62 Completes Patient Enrollment 62 TG MV 62 Oncologic 62 EVEREST II 62 Interspinous Spacer 62 ASH Annual Meeting 62 multicentre randomized controlled 62 Pafuramidine 62 Hepatotoxicity 62 Oral Insulin Capsule 62 Teva Provides Update 62 registrational Phase 62 ENESTnd 62 CorMatrix 62 APEX PD 62 fosbretabulin 62 Tissue Engineered 62 Breast Brachytherapy 62 Glufosfamide 62 Degarelix 62 recurrent glioma 62 BRIM3 62 LungSign TM 62 DermTech International 62 Patient Enrollment 62 Biomarker Study 62 CAPRIE 62 Initiate Phase III 62 DAPT Study 62 First Patient Enrolled 61 CAMMS# 61 Successfully Completes Phase 61 Val HeFT 61 PROTECT AF 61 Randomized Controlled 61 Myoblast 61 PRESEPT 61 randomized Phase IIb 61 acyclovir Lauriad R 61 assessing T DM1 61 CALGB # [002] 61 Gastric Cancer 61 Rotary VAD 61 Prostate Cancer Prevention 61 phase III isavuconazole 61 Stent Thrombosis 61 BR.# 61 Randomized Study 61 Randomized Phase II 61 Randomized controlled 61 M.D. Ph.D. 61 Motesanib 61 NSABP B 61 Tesetaxel 61 rALLy clinical trial 61 YONDELIS 61 Drug Eluting Coronary Stent 61 Hedgehog Pathway Inhibitor 61 Luveniq 61 Phase Ib Clinical Trial 61 PFO migraine 61 Renal Cancer 61 Medtronic CoreValve 61 RhuDex 61 BCIRG 61 CUSTOM III 61 Acute Myocardial Infarction 61 Demonstrates Sustained 61 ASCO GI 61 Cellular Therapies 61 Eluting Coronary Stent System 61 Randomized Evaluation 61 Phase III ThermoDox 61 Hormone Refractory Prostate Cancer 61 MIVI III 61 Autologous Stem Cell Transplantation 61 Confirms Efficacy 61 Phase IIb kidney transplant 61 Seasonal Influenza Vaccine 61 Surgical Treatment 61 Carotid Revascularization Endarterectomy vs. 61 ZACTIMA 61 OvaRex ® MAb 61 Investigational Treatment 61 Initiates Phase III 61 Epidemiological Studies Unit 61 Rilonacept 61 Deforolimus 61 Prospective Multicenter 61 Aggressive Reduction 61 tramiprosate Alzhemed TM 61 Hsp# Inhibitor 61 dose escalation clinical 61 Pivotal Study 61 Podium Presentation 61 See CLINICAL PHARMACOLOGY 61 Phase IIb Trial 61 Phase 1b clinical trials 60 Zenvia Phase III 60 Phase 2b RESTORE CLI 60 Oral Calcitonin 60 EURIDIS 60 Saladax Biomedical 60 Prolongs Survival 60 Ceflatonin R 60 Clinical Trial Results 60 Metametrix 60 AVN# Phase 60 PERSEUS 60 randomized controlled multicenter 60 phase IIb III 60 pharmacokinetic PK study 60 Tuberculosis Vaccine 60 Investigational Drug 60 Hepatocellular Carcinoma 60 IMPACT DCM 60 Systemic Sclerosis 60 Diamyd Medical Diamyd 60 Patient Treated 60 SPIRIT FIRST 60 FIX HF 5 60 Meets Primary Endpoint 60 Randomized Clinical Trial 60 NCIC CTG 60 PLCO 60 MAGE A3 ASCI 60 Edge STudy 60 Therapeutic Vaccine 60 Cloretazine ® 60 Initiates Clinical Trial 60 Ovarian Cancer Screening 60 phase IIIb 60 blinded randomized placebo controlled 60 AMEX RGN 60 Eluting Stent 60 Acute Heart Failure 60 Pulmonary Arterial Hypertension 60 Immunomedics Announces 60 ADVANCE PD 60 Genasense ® 60 Nicotine Vaccine 60 Receives CE Marking 60 GELA 60 SUTENT ® 60 phase Ib clinical 60 Patient Outcomes 60 Therapeutics TCT scientific 60 HDL Selective Delipidation 60 FOLOTYN ® 60 First Patient Dosed 60 Dose Ranging Study 60 lexidronam injection 60 AACR Meeting 60 Randomized Phase III 60 RE MODEL 60 patientswith 60 Advanced Melanoma 60 placebo controlled Phase III 60 Angiox ® 60 Phase Ib study 60 Heterozygous Familial Hypercholesterolemia 60 Aneurysm Repair 60 Coronary Revascularization 60 Pooled Analysis 60 HCV Protease Inhibitor 60 LEUKINE 60 Therapeutics TCT 60 GW# [003] 60 Advaxis Phase 60 HDAC Inhibitor 60 Pivotal Phase II 60 WorldHeart Announces 60 Temsirolimus 60 Infarct 60 Myocet 60 Neoadjuvant Chemotherapy 60 Cardiac Stem Cell 60 Epeius Biotechnologies Corporation 60 Molecular Diagnostic Test 60 Enrolling Patients 60 Angiox R 60 Gynecologic Oncology Group 60 Raptiva R 60 Prostate Cancer Vaccine 60 Safinamide 60 prospective nonrandomized 60 Mycophenolate Mofetil 60 ImmuKnow R 60 INSPIRE Trial Phase III 60 Patient Registry 60 VESTASYNC 60 NAVISTAR R 59 Patient Enrolment 59 Maple Leaf HIFU 59 Files IND 59 Pirfenidone 59 relapsed MM 59 AVERROES 59 Romiplostim 59 Phase III ADT 59 OvaRex MAb 59 AASLD Meeting 59 XIENCE V Stent System 59 Bucindolol 59 Kamada AAT 59 Initiates Clinical 59 Bazedoxifene 59 Sipuleucel T 59 Severe Sepsis 59 Cholesterol Levels SPARCL 59 BLP# Liposome Vaccine 59 relapsing remitting MS RRMS 59 Adjuvant Treatment 59 Endurant 59 Phase III placebo controlled 59 phase IIb clinical 59 Percutaneous Hepatic Perfusion PHP 59 Xelox 59 Antithrombotic 59 Preclinical Models 59 Metastatic Melanoma 59 Raptiva ® 59 Paroxysmal Atrial Fibrillation 59 TAXUS IV 59 Sapacitabine 59 Manja Bouman CEO 59 Cytori Therapeutics NASDAQ CYTX 59 Catheter Ablation 59 Study Evaluating 59 Spirus Medical 59 PRECISE trial 59 Daclizumab 59 Uterine Fibroid Embolization 59 Renal Cell Carcinoma RCC 59 prospective multicenter 59 TM Everolimus Eluting 59 PHX# 59 ENGAGE AF TIMI 59 REMEDIAL II 59 Cloretazine 59 OvaDx 59 Oral Insulin 59 Ridaforolimus 59 Novel Antibiotic 59 Imaging Diagnostic 59 Valve Replacement 59 Preclinical Study 59 Initiate Phase 59 Male Infertility 59 multicenter Phase II 59 Soft Tissue Sarcoma 59 Omacetaxine 59 STRIDE PD 59 Heart Transplant Recipients 59 SNT-MC#/idebenone 59 CyberKnife Radiosurgery 59 Infectious Disease Testing 59 Phase 1b Clinical Trial 59 multicenter prospective 59 multicenter phase 59 Clinical Evaluation 59 Nipent R 59 EOquin TM 59 Drug Formulation 59 BRIM2 59 CLARITY study 59 Phase 2b Trial 59 Liprotamase 59 Phase 2a preventative 59 Female Urology 59 Initiated Phase 59 ST Elevation Myocardial 59 Terumo Heart Inc. 59 Heartscape Technologies 59 Improves Outcomes 59 Granted Orphan Drug 59 Nitazoxanide 59 dual endothelin receptor antagonist 59 LibiGel Phase III 59 QOPI 59 EXPLORE Xa 59 PrevOnco 59 Ozarelix 59 Completes Enrollment 59 InNexus Biotechnology 59 metastatic castration resistant 59 docetaxel Taxotere ® 59 Embolic Protection Device 59 ARIXTRA R 59 MYTHOS trial 59 Microplasmin 59 Brentuximab Vedotin SGN 59 hyaluronidase enzyme 59 Adenoma 59 Shows Promise Against 59 Pyridorin 59 plerixafor 59 Digital Mammographic Imaging 59 Neoadjuvant 59 Bosutinib 59 Phase IIIb study 59 NCI Cancer 59 Chicago Multidisciplinary Symposium 59 ACRIN 59 CONBRIZA 59 Tezampanel 59 Atypical Hemolytic Uremic Syndrome 59 Pivotal Phase 59 Investigational Compound 59 Hematological 59 Initiate Clinical Trial 59 Tumor Microenvironment 59 Phase IIIb 59 GENASIS 59 Investigator Initiated 59 EDEMA3 59 Receives Orphan Drug Designation 59 Onrigin 59 Late Breaker 59 Dr. Pingpank 59 INTEGRILIN R 59 multicenter Phase III 58 Gastrointestinal Oncology 58 Uterine Cancer 58 Tanespimycin 58 ICAAC IDSA 58 Completes Dosing 58 Combination Treatment 58 NCCTG N# 58 Metastatic Colorectal Cancer 58 phase IIa 58 Non Invasive Treatment 58 Psoriasis Drug 58 Teriflunomide 58 Expedited Review 58 Treatment Shows Promise 58 Multicenter Automatic Defibrillator Implantation 58 Basilea Toctino R 58 DuraHeart TM 58 Talabostat 58 miRview meso 58 ASBMR 58 cisplatin gemcitabine 58 Lung Cancer Drug 58 Intravenous Formulation 58 Levacor 58 Phase 2a Clinical Trial 58 Advanced Renal Cell 58 Percutaneous Tibial Nerve Stimulation 58 Obtains CE Mark 58 Intervention Effectiveness 58 IMPACT IMmunotherapy 58 Vicriviroc 58 ISTODAX ® 58 ClinicalTrials.gov Identifier NCT# 58 Hematology Molecular Pathology 58 Melphalan 58 FOLFIRI chemotherapy 58 Arpida Ltd. 58 Adverse Event 58 Malignant Lymphoma 58 II Clinical Trial 58 ThermoDox ® clinical 58 Randomized Clinical Trials 58 Pemetrexed 58 Sanofi aventis EURONEXT SAN 58 Truvada tablets 58 trastuzumab DM1 T DM1 58 treatment naive genotype 58 Alocrest 58 TNFerade TM 58 Cutaneous T 58 Personalized Immunotherapy 58 Carotid Stenting 58 Circulatory Support 58 Fondaparinux 58 Medidur TM FA 58 StemEx 58 Phase 2a Trial 58 MEND CABG 58 recurrent malignant glioma 58 Pivotal Trials 58 Gastrointestinal Cancers 58 DIRECT Trial 58 Multicenter Trial 58 Talactoferrin 58 Cardiovascular Outcomes 58 Chronic Liver Disease 58 Novel Oral 58 COSIRA trial 58 ISEL 58 multicenter Phase 58 number NCT# ClinicalTrials.gov 58 Liver Tumors 58 Sustained Efficacy 58 ALN VSP Phase 58 Bipolar Disorders 58 GEM OS2 58 Dalbavancin 58 Advanced Neuroendocrine Tumors 58 UPLYSO 58 NeuroStar TMS Therapy 58 Multicenter 58 Screening Trial DMIST 58 vinorelbine tartrate 58 Addrenex Pharmaceuticals 58 Minimally Invasive Procedure 58 ASCO GU 58 Belatacept 58 Ranolazine 58 HepaSphere 58 balsalazide tablet 58 Glucosamine Chondroitin Arthritis 58 phase IIb trial 58 buccal spray 58 Antiepileptic Drug 58 Vascugel 58 PRoFESS 58 Augment Injectable 58 TAXUS ATLAS 58 Malignant Melanoma 58 HCV SPRINT 58 Postgraduate Course 58 ThermoDox R 58 mg/m2 cohort 58 Early Relapsing Multiple 58 Phase IIb Clinical Trial 58 Multicentre 58 Novel Vaccine 58 CCX# B 58 JenaValve 58 oral ridaforolimus 58 Improve Diagnosis 58 SPRYCEL ® 58 Severe Asthma 58 ALSYMPCA 58 Image Guided 58 IIa Clinical Trial 58 TASKi3 58 Clinical Trial Evaluating 58 Spinal Disc 58 Randomized Phase 58 Raloxifene STAR 58 Confirmatory Phase 58 Bone Marrow Transplants 58 Maven Semantic 58 DASISION 58 Inflammatory Markers 58 Amorcyte 58 FDA Approvals 58 Radioimmunotherapy 58 budesonide foam 58 #-# Full Text 58 Annual Transcatheter Cardiovascular 58 Am J Geriatr 58 Diagnostic Tests 58 cetrorelix pamoate 58 Treat Parkinson Disease 58 Single Incision 58 ABSORB trial 58 TCAI 58 Demonstrates Efficacy 58 metastatic androgen independent 58 ANN INTERN MED 58 AFREZZA TM 58 Phase #b/#a 58 Guidelines Issued 58 Adjuvant Breast Cancer 58 Treating Chronic 58 Glaucoma Treatment 58 Microalbuminuria 58 PROMUS R 58 recurrent glioblastoma multiforme 58 Spine Patient Outcomes 58 Carotid Endarterectomy 58 Hemodialysis Patients 58 DuraHeart 58 CARE HF 58 Chronic Lymphocytic Leukemia 58 Power3 Medical 58 galiximab 58 metastatic hormone refractory 58 Vaccine Adjuvants 58 Interventional Cardiologists 58 Prostate Screening 58 Transcatheter 58 ONTARGET 58 #:#-# [024] 58 Dacogen decitabine 58 Patients Treated With 58 R vitespen 58 Mitral Valve Repair 58 Phase IIA 58 randomized Phase III 57 Pandemic Influenza Vaccines 57 dose escalation phase 57 Treated Patients 57 ChronVac C 57 multicentre prospective 57 Randomized Double Blind 57 PROTEGE 57 Complicated Skin 57 Valopicitabine 57 Bayer HealthCare Onyx Pharmaceuticals 57 EVICEL 57 Microwave Ablation System 57 Intervention Trial GAIT 57 Crit Rev 57 Ultrasonic Wound 57 Biodesix 57 MYCAMINE 57 multicenter randomized Phase 57 R lenalidomide 57 EnteroMedics proprietary neuroblocking technology 57 Breast Carcinoma 57 Kinase Inhibitors 57 ST Segment Elevation 57 SPIRIT IV 57 Heart Failure Patients 57 ExCell study 57 Peripheral Arterial 57 Dual Antiplatelet Therapy 57 Commences Phase 57 PreCISe 57 Chelation Therapy 57 ABSORB clinical 57 BARI 2D 57 evaluating Prochymal 57 Bendamustine 57 Deutsches Herzzentrum 57 Prednisone Against Refractory 57 Slows Progression 57 Relapsing Multiple Sclerosis 57 Romark Laboratories 57 Eluting 57 Cancer Patients Treated 57 Immunosuppressant 57 RE LY 57 Demonstrate Significant 57 Cardiovascular Therapeutics 57 First Patient Treated 57 nasal calcitonin product 57 Begins Dosing 57 Virus Linked 57 Interferon Gamma 57 Double Blind Placebo 57 multicenter randomized Phase III 57 Anticoagulation 57 HPTN 57 Antitumor Activity 57 IND Filing 57 Inclinix 57 Elagolix 57 IMiDs ® compound 57 Optovue 57 Antibody Therapeutics 57 Drug Shows Promise 57 ProEthic Pharmaceuticals 57 SABCS 57 Orqis Medical 57 PROLARIS 57 MKC# MKC# PP 57 BRILINTA 57 initiated Phase Ib 57 Memgen 57 Low Incidence 57 Stent Restenosis 57 Newly Diagnosed Multiple Myeloma 57 Vaccine Adjuvant 57 Monoclonal antibody 57 CIMZIA TM certolizumab pegol 57 Signal Genetics 57 PROSTASCINT R 57 SWX RO SWX ROG 57 ongoing Phase 1b 57 AACR IASLC Joint 57 ADMIRE HF 57 Aerie Pharmaceuticals 57 Tramiprosate ALZHEMED TM 57 CYT# potent vascular disrupting 57 Endovascular Valve Edge 57 Phase 1a clinical 57 Acute Liver Failure 57 Pregnancy Outcomes 57 Guidelines Recommend 57 Warfarin Coumadin 57 Corautus Genetics 57 Enzyme Replacement Therapy 57 ALTROPANE 57 Group RTOG 57 Arterial Disease 57 HORIZONS AMI trial 57 p# biomarker 57 Therapy Evaluation 57 MGd 57 Diagnostic Ultrasound 57 prospective multicentre 57 AIR CF1 57 Zilver PTX Drug Eluting 57 epoetin alpha 57 Othera Pharmaceuticals Inc. 57 Successfully Treats 57 Stereotactic Body Radiation Therapy 57 Platelet Inhibition 57 Schizophrenia Treatment 57 Proteo 57 sorafenib tablets 57 R Perfexion TM 57 Stenting Trial CREST 57 Zestra R 57 Ophena 57 NO# [002] 57 ELACYT 57 lorcaserin Phase 57 IMPACT DCM trial 57 visceral metastases 57 Molecular Diagnostic 57 nucleotide analogue 57 clevidipine 57 allogeneic hematopoietic cell 57 MedPulser 57 Castration Resistant Prostate Cancer 57 Apixaban 57 Acute Stroke 57 includes Dideco CarboMedics 57 LUX Lung 57 Aplidin R 57 relapsing multiple sclerosis 57 Dose Ranging 57 HQK 57 kidney urologic 57 KRN# 57 HuMax TAC 57 Renal Artery 57 Adjunctive Therapy 57 Gastric Ulcer 57 StemEx R 57 UroVysion 57 ACOMPLIA R 57 Romidepsin 57 Acute Ischemic Stroke 57 Colorectal Cancer CRC 57 Hematologic 57 Syndax Pharmaceuticals Inc. 57 AA Amyloidosis 57 Toremifene 57 Virulizin ® 57 Curaxin CBLC# 57 VEITHsymposium 57 Ichor Medical Systems 57 IMPACT DCM clinical 57 metastatic colorectal 57 GRAVITAS trial 57 PF # [002] 57 Lung Cancer Trial 57 evaluating mipomersen 57 Phase 2b Study 57 phase III ACCLAIM 57 Sunesis Pharma 57 Unstable Angina 57 Dacogen injection 57 Vascular Grafts 57 Postdoctoral Position 57 YONDELIS R 57 Intrinsic Imaging 57 metastatic gastric 57 Cethrin R 57 Fast Track Status 57 Single Dose 57 Chronic Heart Failure 57 Saxagliptin 57 RNAi Therapeutic 57 Patients Receiving 57 GEM OS1 57 sorafenib Nexavar 57 ASSERT 57 identifier NCT# 57 ACCLAIM II 57 phase Ib 57 Perforomist ™ Inhalation Solution 57 Adult Stem Cell Therapy 57 ONTARGET R 57 Allograft 57 Enzastaurin 57 Urology Gynecology 57 Hypertriglyceridemia 57 forodesine 57 Diabetic Macular Edema 57 PRAECIS PHARMACEUTICALS INCORPORATED 57 PANVAC VF 57 PSMA ADC 57 prostate cancer HRPC 57 compound INCB# 57 Anti Infective 57 Naive Patients 57 prospective multicenter randomized 57 RIO Lipids 57 AOD# [002] 57 fidaxomicin Phase 3 57 Antiarrhythmic 57 PROMUS Element Everolimus Eluting 57 Critical Limb Ischemia CLI 57 REGENERX BIOPHARMACEUTICALS INC. 57 PERSEUS clinical program 57 Bioequivalence 57 CRMD# 57 Decompensated Heart Failure 57 Adjuvant Chemotherapy 57 Regado Biosciences 57 ™ Everolimus Eluting 57 HER2 Positive 57 Shows Efficacy 57 TACI Ig 57 Myelodysplastic Syndrome MDS 57 telomerase therapeutic 57 Implantable Device 57 Teplizumab 57 Certican 57 OMP #R# 57 Diabetic Foot Ulcer 57 IRX Therapeutics 57 Tikvah Therapeutics 57 Shows Promising 57 comparing alemtuzumab 57 GSK# [001] 57 Pertuzumab 57 Parathyroid Hormone 57 Archexin 57 Cethromycin 57 MIST II 57 pharmacogenomic translational research 57 personalized cellular immunotherapy 57 Recurrent Breast Cancer 57 ERYtech Pharma 57 CIBMTR 57 ANTEGREN 57 JAK2 Inhibitor 57 Prostate Lung Colorectal 57 Parathyroid 57 MolecularMD 56 Clinical Trial Enrollment 56 Phase 1b clinical 56 Temodar ® 56 ELCAP 56 Nasdaq ACEL 56 CRLX# 56 Glatiramer Acetate 56 Registry NOPR 56 de novo kidney transplant 56 Diabetic Nephropathy 56 Controlled Study 56 Antiplatelet Therapy 56 Vaccine Protects Against 56 Etubics 56 FDA Okays 56 Endoscopic Ablation System 56 Chronic Myeloid Leukemia 56 Vaccine Trials 56 AIR2 Trial 56 Computed Tomographic 56 Motexafin Gadolinium 56 Cytometry 56 Newly Diagnosed Breast Cancer 56 Phase Ia 56 Cervical Dysplasia 56 NCCN Clinical Practice Guidelines 56 TRO# 56 Heart Failure Treatment 56 Recurrent Prostate Cancer 56 Vaccine Trial 56 novel oral anticoagulant 56 immunotherapeutic vaccine 56 Arzerra TM 56 Ganite ® 56 Transdermal Delivery 56 Sicel Technologies Inc. 56 Eur J 56 Gets FDA Clearance 56 Sevelamer 56 ENLIGHT 56 Diabetic Macular Edema DME 56 UEGW 56 familial amyloidotic polyneuropathy FAP 56 refractory metastatic 56 BrachySil TM 56 Cancer Immunotherapy 56 Teriparatide 56 AVADO 56 Broncus Technologies 56 placebo controlled clinical 56 CT Angiography 56 Anti CD# Antibody 56 Begin Clinical Trials 56 Aortic Valve Replacement 56 Anturol TM 56 Arimidex Tamoxifen Alone 56 Hernia Repair 56 Long Term Efficacy 56 Apaziquone 56 Anti Inflammatory Drug 56 By JENNIFER LEARN 56 NDA Submission 56 Patients Enrolled 56 RECORD1 56 TCA Cellular 56 Transdermal Patch 56 prospective randomized multicenter 56 Anti Tumor Activity 56 Files Investigational 56 Fulvestrant 56 Velcade bortezomib 56 Relapsed Multiple Myeloma 56 midstage clinical 56 BridgePoint Medical 56 Replacement Therapy 56 Psoriasis Treatment 56 Annual ICAAC 56 Serious Adverse Events 56 Adjuvant Colon Cancer 56 Cardiovascular Imaging 56 ToGA 56 Urocortin 2 56 pivotal bioequivalence 56 intravesical infusion therapy 56 Preclinical Data 56 SIR Spheres 56 Thrombophilia 56 Lung Cancer Survival 56 Gastrointestinal Cancer 56 Pazopanib 56 COMFORT II 56 myoblast therapy 56 Anticancer Agent 56 Bare Metal Stent 56 GAMMAGARD 56 Poster Discussion 56 Lymphoma Patients 56 Proc Am Soc 56 HCV RESPOND 2 56 Clinical Antipsychotic Trials 56 Carotid 56 Peripheral Stent 56 REMINYL ® 56 Lung Flute ® 56 APEX AMI trial 56 Upstream Biosciences 56 Orphan Status 56 CardioVascular BioTherapeutics Inc. 56 Cervical Cancer Screening 56 initiated Phase 1b 56 metastatic pancreatic 56 NSABP 56 Schizophrenia Drug 56 Ovarian PLCO Cancer 56 Nymox NX 56 CURE AF 56 STENT 56 Triapine 56 Irbesartan 56 cediranib 56 Lung Cancer Screening 56 Acute Renal Failure 56 Poster Presentations 56 Pregnancy Registry 56 Thoraxcenter Erasmus University 56 Proellex TM 56 Gentamicin Surgical Implant 56 Randomized Double blind 56 Mammography Screening 56 EASE Trial 56 Renal Impairment 56 Inhaled Liposomal Ciprofloxacin 56 VIVUS Qnexa 56 Clinical Oncology Annual Meeting 56 Interventional Procedures 56 Coronary Artery Bypass Graft 56 Pediatric Rheumatology 56 Evoltra 56 Hepatocellular Carcinoma HCC 56 undergoing elective percutaneous 56 EndoBarrier ™ 56 TRANSDUR ™ 56 Myelodysplastic Syndrome 56 bepotastine besilate nasal spray 56 Gastrointestinal Cancers Symposium 56 NCT# ClinicalTrials.gov 56 Bioartificial Liver 56 NKI AVL 56 Epratuzumab 56 Cordis Endovascular 56 Receives Approvable Letter 56 Lupus Nephritis 56 BrainGate TM 56 Vaccine Immunology 56 Respiratory Viral Panel 56 J Clin 56 Kahalalide F 56 Commercialize Novel 56 Diabetic Neuropathy 56 Topline Results 56 Hematology Meeting 56 Accelovance 56 Hepatitis B Vaccine 56 BRAF mutated 56 ASCEND HF 56 Randomised 56 Announces FDA Clearance 56 Demonstrates Positive 56 Radiology Imaging Network ACRIN 56 Cardioxyl Pharmaceuticals 56 Clinical Efficacy 56 Kidney Transplant Patients 56 Oncology Compounds 56 Connective Tissue Oncology 56 docetaxel cisplatin 56 orally inhaled migraine 56 Plaque Psoriasis 56 Ophena TM 56 Adaptive Radiation Therapy 56 mITT population 56 Receives Orphan Drug 56 Metastatic Renal Cell Carcinoma 56 Guillermo Torre Amione 56 TARGIT 56 TASKi2 56 Dupuytren Disease 56 eritoran 56 PIX# [002] 56 TOPAMAX R 56 Cardiotoxicity 56 Lovaxin C 56 multicentre randomized 56 Dr. Gussak 56 neratinib 56 Dr. Eberhard Grube 56 Semafore Pharmaceuticals